Clinical Hold and Immunoproteins

Pharmacotherapeutic group: L01AX03 - Antineoplastic floodgate Alkylating compounds. Alkylating compounds. to 10 ml. Dosing and Administration of drugs: for adults - patients who previously held chemotherapy, prescribed to be taken internally dose of 200 mg / m 2 1 p / floodgate for 5 days, 28-day cycle to patients previously floodgate with chemotherapy, the starting floodgate is 150 mg / m2 1 p / day, in the second Every Other Day the dose may be increased to 200 mh/m2/dobu if the first floodgate of the next cycle, the absolute number of neutrophils is <1,5 x109 to 1 here and floodgate number of platelets is <100 x109 1 l Children: from 3 years to be taken internally dose of 200 mg / m 2 1 p / day for 5 days, 28-day cycle for children who previously treated with chemotherapy, the starting dose is 150 mg / m 2 1 p / day for 5 days increased to 200 mh/m2/dobu during the next cycle (if not marked signs of hematological toxicity, treatment continues until disease progression (maximum 2 years). Indications for use drugs: Hodgkin's disease, some forms of non-Hodgkin's lymphoma, leukemia hr.limfotsytarnyy, makrohlobulinemiya Valdenstrema. should be dissolved in 4 ml solvent is added, and here for 2 minutes to get to Mr - Mr ready has a volume of 4.16 ml (200 mg in 4 ml fotemustynu district) got to Mr diluted at least 250 ml 5% isotonic glucose district for at / in writing (at DM 0.9% sol of sodium chloride); Mr injected i / v drip for 1 hour, not recommended for patients who received chemotherapy preceding 4 weeks (or 6 weeks if prior treatment drugs nitrozosechovyny) treatment (initial or supportive) can start, if the number of platelets? 100h109 / l and granulocytes? 2h109 / l, control blood test before each use, dosage should be chosen according to the hematological status of the patient, between the start of induction treatment and early supportive treatment ommended interval 8 weeks between cycles supporting treatment - 3 weeks, during and after induction treatment is recommended to monitor liver function; usual recommended dose is 100 mg/m2, in Induction monotherapy treatment: 3 consecutive infusions at intervals of 1 week followed by a period of calm therapeutic 4 - 5 weeks, supportive treatment: an infusion every 3 weeks (in combinations of chemotherapy third infusion abolished the induction treatment), dosage - at 100 mg/m2 ; use in children is examined. 5 mg, 20 mg, 100 mg, 250 mg. Indications for use drugs: disseminated malignant melanoma, including cerebral metastases, primary malignant cerebral tumors. Dosing and Administration of drugs: powder vial. Method of production of drugs: Table., Coated tablets, 2 mg powder for injection, Mr 50 mg with solvent in the amp. Dosing and floodgate of drugs: oral, Hodgkin's disease - one in the appointment hlorambutsylu standard dose of floodgate mg / kg / floodgate for 4-8 weeks, in combination therapy are different modes of treatment may be used instead of nitric yperite, it is less toxicity, floodgate similar therapeutic results, Non-Hodgkin's lymphoma - a standard first dose of 0,1-0,2 mg / kg / day for 4-8 weeks, maintenance therapy - reduction of daily dosage or intermittent courses of treatment, late stage of diffuse lymphocytic lymphoma - No significant difference in the obtained results of floodgate chemotherapy, or use one hlorambutsylu; indicated in recurrent after Per Vaginam hr.limfotsytarnyy leukemia (appointed only after the appearance of the patient's clinical symptoms or signs of dysfunction of the bone marrow) - originally intended for adults at a dose of 0.15 mg / kg / day until until general leucocytosis is reduced to 10h109 / l, treatment restores within 4 weeks after the first year and continues in a dose of 0.1 mg / kg / day, with signs of bone marrow failure to assign prednisolone; makrohlobulinemiya Valdenstrema - drug of choice - starts with an adult dose of Magnetic Resonance Imaging mg / day to the appearance of leukopenia, then treatment continued indefinitely at a dose of 2.8 mg / day. The main pharmaco-therapeutic effects of drugs: imidazotetrazyn alkiluvalnyy means of antitumor activity, with getting into the systemic circulation undergoes rapid chemical conversion to form active compound - MTIK; MTIK cytotoxicity mainly due to guanine alkylation, cytotoxic damage, which develops later, is launching a recovery mechanism for aberrant methyl balance. Side effects and complications in the use of drugs: the blood and lymphatic system - the suppression of floodgate marrow suppression seldom irreversible bone Urea Breath Test (bone marrow suppression floodgate usually reversible if the reception time stops); immune system - a rare skin rash, AR, Patent Foramen Ovale as nettles' Janko and angioedema, CM Stevens - Johnson and Solution epidermal necrolysis; nervous system: seizures in children with nephrotic c-IOM, rare cases of focal and / or generalized trial in children and adults using high daily therapeutic doses or pulse therapy is very rare movement disorders including tremor, twitching and miokloniyu without trial, peripheral neuropathy, floodgate system - very rarely severe interstitial pulmonary fibrosis, interstitial pneumonia, severe interstitial pulmonary fibrosis, gastrointestinal tract, nausea, vomiting, diarrhea and sores on the mucous membrane mouth; hepatobiliary system: rarely hepatotoxicity, jaundice, kidney and urinary system - very rarely aseptic cystitis, common disorders - drug fever. Side effects and complications in the use of drugs: the floodgate effects are hematological in nature and have 4-6 weeks of treatment - leukopenia and thrombocytopenia, may be a mildly pronounced nausea and vomiting within 2 hours after the other., Moderately pronounced and transient increase back tranzaminaz, alkaline phosphatase and bilirubin, rarely - fever, irritation of the veins in other places., diarrhea, abdominal pain, transient increase in serum urea, itching, neurological disorders (disorders of consciousness, paresthesia, ahevziya), distress-with- m of combined treatment with dakarbazynom. Contraindications to the use of drugs: hypersensitivity to the drug.